Introduction of biosimilar DMARDs costsaving to UKNHS

Introduction of biosimilar DMARDs costsaving to UKNHS PharmacoEconomics & Outcomes News 792, p14 - 2 Dec 2017 Introduction of biosimilar DMARDs cost saving to UK NHS The introduction of biosimilar disease-modifying antitrheumatic drugs (DMARDs) in the UK appears to be cost saving to the NHS, according to findings of a study published in BioDrugs. Data from the DEFINE database (March 2014–September 2017) were used to investigate the impact of introduction of infliximab biosimilars (Inflectra and Remsima) and etanercept biosimilar (Benepali) in UK NHS hospitals on the utilisation of biological DMARDs and the NHS budget. Cumulative cost savings associated with the introduction of infliximab and etanercept biosimilars ** totalled £38.8 million over a two-year period. Between March 2015 and February 2016, savings included £1 373 001 due to reduction in the price of branded infliximab (Remicade), and £877 422 and £415 549 due switching from Remicade to Inflectra and Remsima, respectively. Between March 2016 and February 2017, savings included £4 080 362 due to reduction in the price of Remicade, £2 714 366 and £5 938 132 due to switching to Inflectra and Remsima, respectively, £14 553 532 due to reduction in the price of branded etanercept (Enbrel), and £8 864 755 due to switching from Enbrel to Benepali. Monthly utilisation of abatacept, adalimumab, certolizumab pegol, golimumab and tocilizumab increased significantly, by between 0.48% and 3.06%. However, overall utilisation of etanercept did not change, and utilisation of infliximab decreased by 0.03% per month. The introduction of infliximab biosimilars significantly reduced the monthly utilisation of branded infliximab, and the introduction of etanercept biosimilar significantly reduced the monthly utilisation of branded etanercept (Enbrel). The introduction of DMARD biosimilars in UK hospitals "resulted in considerable cost savings to the NHS, with the branded products reducing their prices in response to the availability of less expensive biosimilars and competition between the biosimilars themselves," concluded the authors. "This suggests that when a biosimilar is available for a directly comparable branded molecule, price is the key influencing factor in its prescribing," they said. * National Health Service ** British pounds Aladul MI, et al. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs : 10 Nov 2017. Available from: URL: http://doi.org/10.1007/ s40259-017-0252-3 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Introduction of biosimilar DMARDs costsaving to UKNHS

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/introduction-of-biosimilar-dmards-costsaving-to-uknhs-1z0iHxpcBc
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4537-z
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p14 - 2 Dec 2017 Introduction of biosimilar DMARDs cost saving to UK NHS The introduction of biosimilar disease-modifying antitrheumatic drugs (DMARDs) in the UK appears to be cost saving to the NHS, according to findings of a study published in BioDrugs. Data from the DEFINE database (March 2014–September 2017) were used to investigate the impact of introduction of infliximab biosimilars (Inflectra and Remsima) and etanercept biosimilar (Benepali) in UK NHS hospitals on the utilisation of biological DMARDs and the NHS budget. Cumulative cost savings associated with the introduction of infliximab and etanercept biosimilars ** totalled £38.8 million over a two-year period. Between March 2015 and February 2016, savings included £1 373 001 due to reduction in the price of branded infliximab (Remicade), and £877 422 and £415 549 due switching from Remicade to Inflectra and Remsima, respectively. Between March 2016 and February 2017, savings included £4 080 362 due to reduction in the price of Remicade, £2 714 366 and £5 938 132 due to switching to Inflectra and Remsima, respectively, £14 553 532 due to reduction in the price of branded etanercept (Enbrel), and £8 864 755 due to switching from Enbrel to Benepali. Monthly utilisation of abatacept, adalimumab, certolizumab pegol, golimumab and tocilizumab increased significantly, by between 0.48% and 3.06%. However, overall utilisation of etanercept did not change, and utilisation of infliximab decreased by 0.03% per month. The introduction of infliximab biosimilars significantly reduced the monthly utilisation of branded infliximab, and the introduction of etanercept biosimilar significantly reduced the monthly utilisation of branded etanercept (Enbrel). The introduction of DMARD biosimilars in UK hospitals "resulted in considerable cost savings to the NHS, with the branded products reducing their prices in response to the availability of less expensive biosimilars and competition between the biosimilars themselves," concluded the authors. "This suggests that when a biosimilar is available for a directly comparable branded molecule, price is the key influencing factor in its prescribing," they said. * National Health Service ** British pounds Aladul MI, et al. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs : 10 Nov 2017. Available from: URL: http://doi.org/10.1007/ s40259-017-0252-3 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off